Cited by 966Bone Metabolism and DiseasesBone health and osteoporosis researchBone and Dental Protein Studies

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation

Poole, Kenneth E. S., Van Bezooijen, Rutger L., Loveridge, Nigel, Hamersma, Herman, Papapoulos, Socrates E., Löwik, Clemens W., Reeve, Jonathan·2005·The FASEB Journal

DOI 10.1096/fj.05-4221fje

Open this paper in CoChat — free account

Abstract

Osteocytes are the most abundant cells in bone and are ideally located to influence bone turnover through their syncytial relationship with surface bone cells. Osteocyte‐derived signals have remained largely enigmatic, but it was recently reported that human osteocytes secrete sclerostin, an inhibitor of bone formation. Absent sclerostin protein results in the high bone mass clinical disorder sclerosteosis. Here we report that within adult iliac bone, newly embedded osteocytes were negative for sclerostin staining but became positive at or after primary mineralization. The majority of mature osteocytes in mineralized cortical and cancellous bone was positive for sclerostin with diffuse staining along dendrites in the osteocyte canaliculi. These findings provide for the first time in vivo evidence to support the concept that osteocytes secrete sclerostin after they become embedded in a mineralized matrix to limit further bone formation by osteoblasts. Sclerostin did not appear to influence the formation of osteocytes. We propose that sclerostin production by osteocytes may regulate the linear extent of formation and the induction or maintenance of a lining cell phenotype on bone surfaces. In doing so, sclerostin may act as a key inhibitory signal governing skeletal microarchitecture.

Integrity signals

Registry

Crossref · 10.1096/fj.05-4221fje

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Bone Resorption by Osteoclasts
Teitelbaum, S. L. (2000) · Science · doi:10.1126/science.289.5484.1504 · Cited by 3,962
Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
Winkler, D. G., Sutherland, M. K., Geoghegan, J. C., Yu, C., Hayes, T., Skonier, J. E., Shpektor, D., Jonas, M., Kovacevich, B. R., Staehling‐Hampton, K., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg599 · Cited by 1,114
Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cystine Knot–Containing Protein
Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011
Self-citation
Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist
van Bezooijen, R. L., Roelen, B. A. J., Visser, A., van der Wee-Pals, L. J. A., de Wilt, E., Karperien, M., Hamersma, H. A., Papapoulos, S. E., ten Dijke, P., & Löwik, C. W. G. M. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031454 · Cited by 893
Self-citation
Loss of Osteocyte Integrity in Association with Microdamage and Bone Remodeling After Fatigue In Vivo
Verborgt, O., Gibson, G. J., & Schaffler, M. B. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.60 · Cited by 731
Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells
Dobnig, H., & Turner, R. T. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628403 · Cited by 614
Periosteum: biology, regulation, and response to osteoporosis therapies
Allen, M. R., Hock, J. M., & Burr, D. B. (2004) · Bone · doi:10.1016/j.bone.2004.07.014 · Cited by 449
The Death of Osteocytes via Apoptosis Accompanies Estrogen Withdrawal in Human Bone
Tomkinson, A., REEVE, J., Shaw, R. W., & Noble, B. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.9.4200 · Cited by 417
Self-citation

Show all 34 references

Research works printed but not linked: 2

Warmington K., 2004, Sclerostin antagonism in adult rodents, via monoclonal antibody mediated blockade, increases bone mineral density and implicates sclerostin as a key regulator of bone mass during adulthood (Abstract), J. Back Musculoskeletal. Rehabil., 19, S56
10.1210/jc.82.9.3128 · DOI

Sorted by citations

Items 201–300 of 966

Role of Osteocyte-derived Insulin-Like Growth Factor I in Developmental Growth, Modeling, Remodeling, and Regeneration of the Bone
Sheng, M. H. ‐., Lau, K. ‐. W., & Baylink, D. J. (2014) · Journal of Bone Metabolism · doi:10.11005/jbm.2014.21.1.41 · Cited by 86
Destroy to Rebuild: The Connection Between Bone Tissue Remodeling and Matrix Metalloproteinases
Hardy, E., & Fernández-Patrón, C. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00047 · Cited by 86
FGF23 is mainly synthesized by osteocytes in the regularly distributed osteocytic lacunar canalicular system established after physiological bone remodeling
Ubaidus, S., Li, M., Sultana, S., de Freitas, P. H. L., Oda, K., Maeda, T., Takagi, R., & Amizuka, N. (2009) · Journal of Electron Microscopy · doi:10.1093/jmicro/dfp032 · Cited by 85
Sclerostin is expressed in articular cartilage but loss or inhibition does not affect cartilage remodeling during aging or following mechanical injury
Roudier, M. P., Li, X., Niu, Q., Pacheco, E., Pretorius, J. K., Graham, K. C., Yoon, B. P., Gong, J., Warmington, K. S., Ke, H. Z., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.37802 · Cited by 85
Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap–/– Mice, a Model of Recessive Osteogenesis Imperfecta
Grafe, I., Alexander, S., Yang, T., Lietman, C., Homan, E. P., Munivez, E. M., Chen, Y., Jiang, M. M., Bertin, T., Dawson, B., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2776 · Cited by 83
Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study
Chouinard, L., Felx, M., Mellal, N., Varela, A., Mann, P., Jolette, J., Samadfam, R., Smith, S. Y., Locher, K., Buntich, S., et al. (2016) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2016.08.010 · Cited by 84
Capacity of octacalcium phosphate to promote osteoblastic differentiation toward osteocytes in vitro
Sai, Y., Shiwaku, Y., Anada, T., Tsuchiya, K., Takahashi, T., & Suzuki, O. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.01.026 · Cited by 83
Role of Osteocyte-PDL Crosstalk in Tooth Movement via SOST/Sclerostin
Odagaki, N., Ishihara, Y., Wang, Z., Hlaing, E. E., Nakamura, M., Hoshijima, M., Hayano, S., Kawanabe, N., & Kamioka, H. (2018) · Journal of Dental Research · doi:10.1177/0022034518771331 · Cited by 85
The Wnt pathway: An important control mechanism in bone's response to mechanical loading
Choi, R. B., & Robling, A. G. (2021) · Bone · doi:10.1016/j.bone.2021.116087 · Cited by 86
Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment
Sinder, B. P., Salemi, J. D., Ominsky, M. S., Caird, M. S., Marini, J. C., & Kozloff, K. M. (2014) · Bone · doi:10.1016/j.bone.2014.10.012 · Cited by 84
Changes in 3-dimensional bone structure indices in hypoparathyroid patients treated with PTH(1-84): A randomized controlled study
Sikjær, T., Rejnmark, L., Thomsen, J. S., Tietze, A., Brüel, A., Andersen, G., & Mosekilde, L. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1493 · Cited by 82
Wnt-modified materials mediate asymmetric stem cell division to direct human osteogenic tissue formation for bone repair
Okuchi, Y., Reeves, J., Ng, S. S., Doro, D. H., Junyent, S., Liu, K. J., Haj, A. J. E., & Habib, S. J. (2020) · Nature Materials · doi:10.1038/s41563-020-0786-5 · Cited by 81
NMR structure of the Wnt modulator protein Sclerostin
Weidauer, S. E., Schmieder, P., Beerbaum, M., Schmitz, W., Oschkinat, H., & Mueller, T. D. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.01.062 · Cited by 81
Matrix Mineralization as a Trigger for Osteocyte Maturation
Irie, K., Ejiri, S., Sakakura, Y., Shibui, T., & Yajima, T. (2008) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.2008.950527 · Cited by 81
Cathepsin K–deficient osteocytes prevent lactation-induced bone loss and parathyroid hormone suppression
Lotinun, S., Ishihara, Y., Nagano, K., Kiviranta, R., Carpentier, V. T., Neff, L., Parkman, V.-J. A., Ide, N., Hu, D. Z., Dann, P. R., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci122936 · Cited by 80
Romosozumab in osteoporosis: yesterday, today and tomorrow
Wu, D., Li, L., Wen, Z., & Wang, G. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04563-z · Cited by 88
Regulatory pathways associated with bone loss and bone marrow adiposity caused by aging, chemotherapy, glucocorticoid therapy and radiotherapy.
Georgiou, K. R., Hui, S. K., & Xian, C. J. (2012) · Europe PMC (PubMed Central) · Cited by 80
Primary Human Osteoblasts Cultured in a 3D Microenvironment Create a Unique Representative Model of Their Differentiation Into Osteocytes
Nasello, G., Alamán‐Díez, P., Schiavi, J., Pérez, M. Á., McNamara, L. M., & García‐Aznar, J. M. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00336 · Cited by 80
Sclerostin levels during growth in children
Kirmani, S., Amin, S., McCready, L. K., Atkinson, E. J., Melton, L. J., Müller, R., & Khosla, S. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1669-z · Cited by 81
Systemic Inflammation Affects Human Osteocyte-Specific Protein and Cytokine Expression
Pathak, J. L., Bakker, A. D., Luyten, F. P., Verschueren, P., Lems, W. F., Klein‐Nulend, J., & Bravenboer, N. (2016) · Calcified Tissue International · doi:10.1007/s00223-016-0116-8 · Cited by 78
Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin
Gatti, D., Viapiana, O., Adami, S., Idolazzi, L., Fracassi, E., & Rossini, M. (2011) · Bone · doi:10.1016/j.bone.2011.11.028 · Cited by 77
Involvement of the Wnt‐ β ‐catenin signalling antagonists, sclerostin and dickkopf‐related protein 1, in chronic periodontitis
Napimoga, M. H., Nametala, C., da Silva, F. L., Miranda, T. S., Bossonaro, J. P., Demasi, A. P. D., & Duarte, P. M. (2014) · Journal Of Clinical Periodontology · doi:10.1111/jcpe.12245 · Cited by 76
Androgen receptor disruption increases the osteogenic response to mechanical loading in male mice
Callewaert, F., Bakker, A. D., Schrooten, J., MEERBEEK, B. V., Verhoeven, G., Boonen, S., & Vanderschueren, D. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.091001 · Cited by 77
Bone and muscle crosstalk in ageing and disease
Kirk, B., Lombardi, G., & Duque, G. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01088-x · Cited by 89
Transcriptional Profiling of Laser Capture Microdissected Subpopulations of the Osteoblast Lineage Provides Insight Into the Early Response to Sclerostin Antibody in Rats
Nioi, P., Taylor, S., Hu, R., Pacheco, E., He, Y. D., Hamadeh, H. K., Pászty, C., Pyrah, I. T. G., Ominsky, M. S., & Boyce, R. W. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2482 · Cited by 74
Extracellular Matrix Mineralization Promotes E11/gp38 Glycoprotein Expression and Drives Osteocytic Differentiation
Prideaux, M., Loveridge, N., Pitsillides, A. A., & Farquharson, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036786 · Cited by 75
Self-citation
The enigmas of bone without osteocytes
Shahar, R., & Dean, M. N. (2013) · BoneKEy Reports · doi:10.1038/bonekey.2013.77 · Cited by 75
Sclerostin Inhibition in the Management of Osteoporosis
Appelman‐Dijkstra, N. M., & Papapoulos, S. E. (2016) · Calcified Tissue International · doi:10.1007/s00223-016-0126-6 · Cited by 74
Self-citation
Anti-Sclerostin Antibodies in Osteoporosis and Other Bone Diseases
Fabre, S., Funck‐Brentano, T., & Cohen-Solal, M. E. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113439 · Cited by 78
Circulating Sclerostin in Disorders of Parathyroid Gland Function
Costa, A. G., Cremers, S., Rubin, M. R., McMahon, D. J., Sliney, J., Lazaretti‐Castro, M., Silverberg, S. J., & Bilezikian, J. P. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0566 · Cited by 74
Prostaglandin E2 Signals Through PTGER2 to Regulate Sclerostin Expression
Genetos, D. C., Yellowley, C. E., & Loots, G. G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017772 · Cited by 74
Bone biology, signaling pathways, and therapeutic targets for osteoporosis
Iñiguez‐Ariza, N. M., & Clarke, B. L. (2015) · Maturitas · doi:10.1016/j.maturitas.2015.07.003 · Cited by 79
Systemic Administration of Sclerostin Antibody Enhances Bone Repair in a Critical-Sized Femoral Defect in a Rat Model
Virk, M. S., Alaee, F., Tang, H., Ominsky, M. S., Ke, H. Z., & Lieberman, J. R. (2013) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.l.00285 · Cited by 73
The effect of TNFα secreted from macrophages activated by titanium particles on osteogenic activity regulated by WNT/BMP signaling in osteoprogenitor cells
Lee, S., Sharma, A. R., Choi, B., Jung, J., Chang, J., Park, S., Salvati, E. A., Purdue, P. E., Song, D., & Nam, J. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.03.005 · Cited by 73
Vascular Calcification and Renal Bone Disorders
Lu, K., Wu, C., Yen, J.-F., & Liu, W.-C. (2014) · The Scientific World JOURNAL · doi:10.1155/2014/637065 · Cited by 73
Increased autophagy in EphrinB2-deficient osteocytes is associated with elevated secondary mineralization and brittle bone
Vrahnas, C., Blank, M., Dite, T. A., Tatarczuch, L., Ansari, N., Crimeen-Irwin, B., Nguyen, H., Forwood, M. R., Hu, Y., Ikegame, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11373-9 · Cited by 70
Loading‐Induced Reduction in Sclerostin as a Mechanism of Subchondral Bone Plate Sclerosis in Mouse Knee Joints During Late‐Stage Osteoarthritis
Jia, H., Ma, X., Wei, Y., Tong, W., Tower, R. J., Chandra, A., Wang, L., Sun, Z., Yang, Z., Badar, F., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40351 · Cited by 72
Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength
Sinder, B. P., WHITE, L. E., Salemi, J. L., Ominsky, M. S., Caird, M. S., Marini, J. C., & Kozloff, K. M. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2737-y · Cited by 71
Anti-osteoporosis therapy and fracture healing
Larsson, S., & Fazzalari, N. L. (2012) · Archives of Orthopaedic and Trauma Surgery · doi:10.1007/s00402-012-1558-8 · Cited by 69
Wnt signaling in bone, kidney, intestine, and adipose tissue and interorgan interaction in aging
Chen, D., Xie, R., Shu, B., LANDAY, A. L., Wei, C., Reiser, J., Spagnoli, A., Torquati, A., Forsyth, C. B., Keshavarzian, A., et al. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13945 · Cited by 69
Control of Bone Matrix Properties by Osteocytes
Creecy, A., Damrath, J. G., & Wallace, J. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.578477 · Cited by 68
The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis
Sølling, A. S., Harsløf, T., & Langdahl, B. L. (2018) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x18775936 · Cited by 67
MECHANISMS IN ENDOCRINOLOGY: Regulation of glucose metabolism by the ghrelin system: multiple players and multiple actions
Heppner, K. M., & Tong, J. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0183 · Cited by 68
Sclerostin Protects Against Vascular Calcification Development in Mice
Maré, A. D., Opdebeeck, B., Neven, E., D’Haese, P. C., & Verhulst, A. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4503 · Cited by 68
Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells
Papanicolaou, S. E., Phipps, R. J., Fyhrie, D. P., & Genetos, D. C. (2009) · Biorheology · doi:10.3233/bir-2009-0550 · Cited by 70
Anabolic and Catabolic Regimens of Human Parathyroid Hormone 1–34 Elicit Bone- and Envelope-Specific Attenuation of Skeletal Effects in Sost-Deficient Mice
Robling, A. G., Kedlaya, R., Ellis, S. N., Childress, P., Bidwell, J. P., Bellido, T., & Turner, C. H. (2011) · Endocrinology · doi:10.1210/en.2011-0049 · Cited by 69
Localization ofSOST/sclerostin in cementocytesin vivoand in mineralizing periodontal ligament cellsin vitro
Jäger, A., Götz, W., Lossdörfer, S., & Rath-Deschner, B. (2009) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.2009.01227.x · Cited by 67
Targeting of androgen receptor in bone reveals a lack of androgen anabolic action and inhibition of osteogenesis
Wiren, K. M., Semirale, A. A., Zhang, X.-W., Woo, A., Tommasini, S. M., Price, C., Schaffler, M. B., & Jepsen, K. J. (2008) · Bone · doi:10.1016/j.bone.2008.04.026 · Cited by 65
Parathyroid hormone 1-34 and skeletal anabolic action
Osagie-Clouard, L., Sanghani‐Kerai, A., Coathup, M. J., Briggs, T. W. R., Bostrom, M. P., & Blunn, G. W. (2017) · Bone and Joint Research · doi:10.1302/2046-3758.61.bjr-2016-0085.r1 · Cited by 67
Sclerostin Antibody Increases Bone Volume and Enhances Implant Fixation in a Rat Model
Virdi, A. S., Liu, M., Sena, K., Maletich, J., McNulty, M. A., Ke, H. Z., & Sumner, D. R. (2012) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.k.00344 · Cited by 64
Determination of Serum and Plasma Sclerostin Concentrations by Enzyme-Linked Immunoassays
McNulty, M. S., Singh, R. J., Li, X., Bergstralh, E. J., & Kumar, R. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0254 · Cited by 64
Rickets in Children: An Update
Gentile, C., & Chiarelli, F. (2021) · Biomedicines · doi:10.3390/biomedicines9070738 · Cited by 63
Negative Regulation of Bone Formation by the Transmembrane Wnt Antagonist Kremen-2
Schulze, J., Seitz, S. A., Saito, H., Schneebauer, M., Marshall, R. P., Baranowsky, A., Busse, B., Schilling, A. F., Friedrich, F. W., Albers, J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010309 · Cited by 63
From skeletal to cardiovascular disease in 12 steps—the evolution of sclerostin as a major player in CKD-MBD
Brandenburg, V. M., D’Haese, P. C., Deck, A., Mekahli, D., Meijers, B. K. I., Neven, E., & Evenepoel, P. (2015) · Pediatric Nephrology · doi:10.1007/s00467-015-3069-7 · Cited by 63
The bone-sparing effects of estrogen and WNT16 are independent of each other
Movérare‐Skrtic, S., Wu, J., Henning, P., Gustafsson, K. L., Sjögren, K., Windahl, S. H., Koskela, A., Tuukkanen, J., Börjesson, A., Lagerquist, M. K., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520408112 · Cited by 63
Sclerostin: Intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders
Pietrzyk, B., Smertka, M., & Chudek, J. T. (2017) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/68739 · Cited by 63
MECHANISMS IN ENDOCRINOLOGY: Bone Marrow Adiposity and bone, a bad romance?
Rharass, T., & Lucas, S. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0182 · Cited by 42
Role of osteocytes in multiple myeloma bone disease
Delgado‐Calle, J., Bellido, T., & Roodman, G. D. (2014) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000090 · Cited by 63
Sclerostin and the regulation of bone formation: Effects in hip osteoarthritis and femoral neck fracture
Power, J., Poole, K. E. S., Bezooijen, R. V., Doube, M., Caballero-Alías, A. M., Löwik, C. W. G. M., Papapoulos, S. E., REEVE, J., & Loveridge, N. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.70 · Cited by 63
Self-citation
Quantitative regional associations between remodeling, modeling, and osteocyte apoptosis and density in rabbit tibial midshafts
Hedgecock, N. L., Hadi, T. M., Chen, A. A., Curtiss, S. B., Martin, R. B., & Hazelwood, S. J. (2006) · Bone · doi:10.1016/j.bone.2006.10.006 · Cited by 62
Milk extracellular vesicles accelerate osteoblastogenesis but impair bone matrix formation
Oliveira, M. C., Arntz, O. J., Davidson, E. N. B., van Lent, P. L. E. M., Koenders, M. I., van der Kraan, P. M., van den Berg, W. B., Ferreira, A. V. M., & van de Loo, F. A. J. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.11.017 · Cited by 62
When, How, and Why a Bone Biopsy Should Be Performed in Patients With Chronic Kidney Disease
Ureña, P., Bover, J., Mazzaferro, S., de Vernejoul, M. C., & Cohen-Solal, M. E. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.09.004 · Cited by 60
Pharmacological and biological therapeutic strategies for osteogenesis imperfecta
Marom, R., Lee, Y., Grafe, I., & Lee, B. (2016) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31532 · Cited by 59
Progress of Signaling Pathways, Stress Pathways and Epigenetics in the Pathogenesis of Skeletal Fluorosis
Qiao, L., Liu, X., He, Y., Zhang, J., Huang, H., Bian, W., Chilufya, M. M., Zhao, Y., & Han, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111932 · Cited by 64
Orthogeriatrics
Falaschi, P., & Marsh, D. (2020) · Practical issues in geriatrics · doi:10.1007/978-3-030-48126-1 · Cited by 113
Identification of osteocyte‐selective proteins
Guo, D., Keightley, A., Guthrie, J. R., Veno, P. A., Harris, S. E., & Bonewald, L. F. (2010) · PROTEOMICS · doi:10.1002/pmic.201000306 · Cited by 62
Low sirtuin 1 levels in human osteoarthritis subchondral osteoblasts lead to abnormal sclerostin expression which decreases Wnt/β-catenin activity
Abed, É., Couchourel, D., Delalandre, A., Duval, N., Pelletier, J., Martel‐Pelletier, J., & Lajeunesse, D. (2013) · Bone · doi:10.1016/j.bone.2013.10.020 · Cited by 60
Pro-inflammatory Cytokines: Cellular and Molecular Drug Targets for Glucocorticoid-induced-osteoporosis via Osteocyte
Wang, T., Yu, X., & He, C. (2018) · Current Drug Targets · doi:10.2174/1389450119666180405094046 · Cited by 61
Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats
McDonald, M., Morse, A., Mikulec, K., Peacock, L., Yu, N., Baldock, P., Birke, O., Liu, M., Ke, H., & Little, D. (2012) · Journal of Orthopaedic Research · doi:10.1002/jor.22109 · Cited by 59
The Emerging Role of Osteocytes in Cancer in Bone
Atkinson, E. G., & Delgado‐Calle, J. (2019) · JBMR Plus · doi:10.1002/jbm4.10186 · Cited by 58
Osteocytes and Skeletal Pathophysiology
Delgado‐Calle, J., & Bellido, T. (2015) · Current Molecular Biology Reports · doi:10.1007/s40610-015-0026-y · Cited by 62
Low bone accrual is associated with osteocyte apoptosis in alcohol-induced osteopenia
Maurel, D. B., Jaffré, C., Rochefort, G. Y., Aveline, P. C., Boisseau, N., Uzbekov, R. E., Gosset, D., Pichon, C., Fazzalari, N. L., Pallu, S., et al. (2011) · Bone · doi:10.1016/j.bone.2011.06.001 · Cited by 58
Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats
Tian, X., Setterberg, R. B., Li, X., Pászty, C., Ke, H. Z., & Jee, W. S. S. (2010) · Bone · doi:10.1016/j.bone.2010.05.032 · Cited by 56
Anabolic Agents and Bone Quality
Sibai, T. A., Morgan, E. F., & Einhorn, T. A. (2010) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-010-1722-9 · Cited by 58
Osteoporosis and Fragility Fractures: currently available pharmacological options and future directions
Dimai, H. P., & Fahrleitner‐Pammer, A. (2022) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2022.101780 · Cited by 58
Estrogen and estrogen receptors mediate the mechanobiology of bone disease and repair
Shi, V. Y., & Morgan, E. F. (2024) · Bone · doi:10.1016/j.bone.2024.117220 · Cited by 64
An update on biomarkers in axial spondyloarthritis
Prajzlerová, K., Bubová, K., Pavelká, K., Šenolt, L., & Filková, M. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.02.002 · Cited by 57
Canalicular Junctions in the Osteocyte Lacuno-Canalicular Network of Cortical Bone
Wittig, N. K., Laugesen, M., Birkbak, M. E., Bach-Gansmo, F. L., Pacureanu, A., Bruns, S., Wendelboe, M. H., Brüel, A., Sørensen, H. O., Thomsen, J. S., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b08478 · Cited by 58
Elevated glucose acts directly on osteocytes to increase sclerostin expression in diabetes
Pacicca, D. M., Brown, T., Watkins, D. J., Kover, K. L., Yan, Y., Prideaux, M., & Bonewald, L. F. (2019) · Scientific Reports · doi:10.1038/s41598-019-52224-3 · Cited by 57
Bone Structure, Development and Bone Biology
Safadi, F. F., Barbe, M. F., Abdelmagid, S. M., Rico, M. C., Aswad, R. A., Litvin, J., & Popoff, S. N. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-347-9_1 · Cited by 75
Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients?
Pelletier, S., Confavreux, C. B., Haesebaert, J., Guebre‐Egziabher, F., Bacchetta, J., Carlier, M.-C., Chardon, L., Laville, M., Chapurlat, R. D., London, G. M., et al. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3127-9 · Cited by 56
Romosozumab in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture
Bhandari, M., Schemitsch, E. H., Karachalios, T. S., Sancheti, P. K., Poolman, R. W., Caminis, J. N., Daizadeh, N. S., Dent-Acosta, R. E., Egbuna, O. I., Chines, A. A., et al. (2020) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.19.01008 · Cited by 56
Bone tissue and histological and molecular events during development of the long bones
Blumer, M. J. F. (2021) · Annals of Anatomy - Anatomischer Anzeiger · doi:10.1016/j.aanat.2021.151704 · Cited by 57
Therapeutic ionizing radiation induced bone loss: a review of in vivo and in vitro findings
Zhang, J., Qiu, X., Xi, K., Hu, W., Pei, H., Nie, J., Wang, Z., Ding, J.-H., Shang, P., Li, B., et al. (2018) · Connective Tissue Research · doi:10.1080/03008207.2018.1439482 · Cited by 55
The Osteocyte as the New Discovery of Therapeutic Options in Rare Bone Diseases
Pathak, J. L., Bravenboer, N., & Klein‐Nulend, J. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00405 · Cited by 57
Bone marrow adipose tissue: Role in bone remodeling and energy metabolism
Tencerová, M., Ferenčáková, M., & Kassem, M. S. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101545 · Cited by 55
Unraveling metalloproteinase function in skeletal biology and disease using genetically altered mice
Aiken, A., & Khokha, R. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2009.07.002 · Cited by 53
Bone disease in primary hyperparathyrodism
Marcocci, C., Cianferotti, L., & Cetani, F. (2012) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x12441869 · Cited by 53
Gingival Crevicular Fluid Levels of Sclerostin, Osteoprotegerin, and Receptor Activator of Nuclear Factor‐κB Ligand in Periodontitis
Ballı, U., Aydoğdu, A., Dede, F. Ö., Türer, Ç. C., & Güven, B. (2015) · Journal of Periodontology · doi:10.1902/jop.2015.150270 · Cited by 54
Estrogen deficiency attenuates fluid flow‐induced [Ca 2+ ] i oscillations and mechanoresponsiveness of MLO‐Y4 osteocytes
Deepak, V., Kayastha, P., & McNamara, L. M. (2017) · The FASEB Journal · doi:10.1096/fj.201601280r · Cited by 57
Monoclonal antibodies for treating osteoporosis
Faienza, M. F., Chiarito, M., D’Amato, G., Colaianni, G., Colucci, S. C., Grano, M., & Brunetti, G. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1401607 · Cited by 52
Mechanotransduction pathways in bone pathobiology
Spyropoulou, A., Karamesinis, K., & Basdra, E. K. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.05.010 · Cited by 55
In Vitro Co-Culture Model of Primary Human Osteoblasts and Osteocytes in Collagen Gels
Skottke, J., Gelinsky, M., & Bernhardt, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081998 · Cited by 53
Reduction of SOST gene promotes bone formation through the Wnt/β‐catenin signalling pathway and compensates particle‐induced osteolysis
Zhang, Z. H., Jia, X., Fang, J. Y., Chai, H., Huang, Q., She, C., Jia, P., Geng, D. C., & Xu, W. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15084 · Cited by 52
Correlates of bone microarchitectural parameters and serum sclerostin levels in men: The STRAMBO study
Szulc, P., Boutroy, S., Vilayphiou, N., Schoppet, M., Rauner, M., Chapurlat, R. D., Hamann, C., & Hofbauer, L. C. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1888 · Cited by 53
Modeling Fluorescence Recovery After Photobleaching in Loaded Bone: Potential Applications in Measuring Fluid and Solute Transport in the Osteocytic Lacunar-Canalicular System
Zhou, X., Novotny, J. E., & Wang, L. (2008) · Annals of Biomedical Engineering · doi:10.1007/s10439-008-9566-0 · Cited by 51
Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels
Jastrzebski, S. L., Kalinowski, J., Stolina, M., Mirza, F., Torreggiani, E., Kalajzić, I., Won, H. Y., Lee, S., & Lorenzo, J. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1773 · Cited by 53
The −9247 T/C polymorphism in the SOST upstream regulatory region that potentially affects C/EBPα and FOXA1 binding is associated with osteoporosis
Huang, Q.-Y., Li, G. H., & Kung, A. W. C. (2009) · Bone · doi:10.1016/j.bone.2009.03.676 · Cited by 52
Lipid Nanoparticle Delivery of siRNA to Osteocytes Leads to Effective Silencing of SOST and Inhibition of Sclerostin In Vivo
Basha, G., Ordobadi, M., Scott, W. R., Cottle, A. G., Liu, Y., Wang, H., & Cullis, P. R. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.68 · Cited by 52
Mechanical and biological properties of chitin/polylactide (PLA)/hydroxyapatite (HAP) composites cast using ionic liquid solutions
Chakravarty, J., Rabbi, M. F., Chalivendra, V., Ferreira, T., & Brigham, C. J. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.10.168 · Cited by 54

Authors: Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J.
Affiliations: University of Cambridge (GB)
Department of Endocrinology and Metabolic Diseases Leiden University Medical Centre Leiden Netherlands
South Africa
Leiden University (NL)
ORCID: Poole, Kenneth E. S.
Loveridge, Nigel
Hamersma, Herman
Papapoulos, Socrates E.
Löwik, Clemens W.
Reeve, Jonathan
Venue: The FASEB Journal
Publisher: Wiley
Published: 2005-08-25
Volume: 19
Issue: 13
Pages: 1842-1844
ISSN: 0892-6638 (ISSN-L)
1530-6860
DOI: 10.1096/fj.05-4221fje
OpenAlex: W1970864109
Cited by: 965
References: 34
Citations by year: 2026: 21 · 2025: 28 · 2024: 32 · 2023: 39 · 2022: 38 · 2021: 45 · 2020: 74 · 2019: 63 · 2018: 55 · 2017: 53 · 2016: 66 · 2015: 67 · 2014: 55 · 2013: 62 · 2012: 63
FWCI: 10.29
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: The FASEB Journal (publishedVersion)
PubMed (publishedVersion)
Funders: Medical Research Council
National Osteoporosis Society
European Commission (LSHM‐CT‐2003‐503020)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Bone and Dental Protein Studies
Keywords: sclerostin, osteocytes, bone formation inhibition, sclerosteosis, osteoblasts, bone mineralization, bone lining cells, bone turnover
MeSH terms: Aged, Alkaline Phosphatase, Antibodies, Monoclonal, Biopsy, Bone and Bones, Bone Development, Bone Diseases, Developmental, Bone Resorption, Cell Differentiation, Coloring Agents, Female, Genetic Markers, Humans, Image Processing, Computer-Assisted, Immunohistochemistry, Male, Microscopy, Fluorescence, Middle Aged, Models, Biological, Osteoblasts, Osteocytes, Osteogenesis, RNA, Messenger, Time Factors, Tolonium Chloride, Signal Transduction, Bone Remodeling, Bone Morphogenetic Proteins, Adaptor Proteins, Signal Transducing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks